Ovarian cancer, Secondary cancers
Results
Phase 2
This trial looked at adavosertib alongside paclitaxel and carboplatin for ovarian cancer that had come back.
It was for women:
who had cancer that had responded to in the past
whose cancer cells had a particular change (mutation) in the p53
Adavosertib is also called MK-1775 and AZD1775.
This trial was open for people to join between 2013 and 2014. The team published the results in 2020. There is a link to more information in the ‘Summary of results’ section below.
Recruitment start: 11 February 2013
Recruitment end: 31 July 2014
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Susie Banerjee
Experimental Cancer Medicine Centre (ECMC)
Merck Sharp & Dohme Ltd
NIHR Clinical Research Network: Cancer
Last reviewed: 18 March 2024
CRUK internal database number: 10187
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
